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SUMMARY 
The presait study was aimed to find out the alteration of NE and 5HT systems in depression, if so in the 
same direction or not and to Had out the clinical response to combined therapy of Imipramine and Amitri-
ptyline, both tricyclic antidepressants. The study group consisted of 39 depressives as defined by I.C-D.'J 
and 17 normal controls. Hamilton Depression Rating Scale was used to assess the severity of depression 
initially and after clinical improvement with drugs. Urinary MHPG and CSF 5HIAA were estimated fin-
al] depressives as per the standard procedure. 
It was found that both urinary MHPG and CSF 5HIAA were lowered in depressives but when indivi-
dual patients were analysed both were not altered in the same direction in a given individual. All tiic 
depressives showed equal therapautic response to combined administration of Imipramine and Amitripiv-
linc 
The Catecholamine (CA) hypothesis 
of affective disorder propose* that some, 
if not all, depressives are associated with 
absolute or relative decrease in catechc-
lames particularly Nor Epinephrine (NE), 
Indoleamine (IA) and Serotonin (5HT) 
(Schildkraut, 1965; van Praag, 1977; 
1978). The previous studies led to two 
concepts— the concept that central amine 
metabolism can play a role in the patho-
genesis of depression and the concept 
that the group of depressions is a hetero-
genous one in biochemical terms. Atleast 
two types of depressions exist-5HT defi-
ciency play a role in the pathogenesis of 
one, while NE deficiency is important in 
the pathogenesis of the other (van Praag, 
1977b). This conclusion raises the new 
question—Can both 5HT and NE metabo-
lism be disturbed in the same patient or 
are the depressions either chiefly 5HT or 
NE deficient. There are studies to show 
that there is interaction between 5HT 
and NE systems (Johnson and Kim, 
1973). The general conclusion is that 
5HT system of the raphe and NE system 
of Locus Goeruleus (LG) may reciprocally 
inhibit one another. 
In the recent years based on the 
hypothesis of 5HT and NE involvement 
several different attepmts have been made 
to develop laboratory tests that might 
predict the response of depressed patients 
to various tricyclic antidepressants 
(TCA). 5HT deficient depressives 
improve in response to compounds consi-
dered to increase the amount of 5HT 
available in the brain c.%. Cloimipramine 
and NE deficient group improve with 
drugs on NE system e.g. Imipramine 
(IMI) and Nortriptyline (NT). It was 
reported by Asberyet al. (1972) that low 
5HIAA (metabolite of 5HT) depressed 
group did not respond to NT whereas 
high 5HlAA-low MHPG (metabolite of 
NE) did. Low 5HIAA group found to 
be non responders to IMI (Goodwin 
and Post, 1975). It was also reported 
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that low 5AIAA group responded better 
to cloimipramine which has marked 
inhibitory effect on the 5HT reuptake 
into neuron. 
Many investigators used MHPG 
levels to differentiate subtypes of depres-
sion (Schildkrut et al., 1978; Palaniappun, 
1980). It is believed that the urinary 
MHPG reflects brain metabolism and 
hence one approach has been to measure 
urinary excretion of MHPG. Maas et al. 
(1972) reported that low MHPG group 
responded better to IMI. It was found 
that all depressives with MHPG excretion 
below 1000 Ug/24 hrs. responded well to 
IMI and Desmethylimipra.nine (DMI). 
Beckman and Goodwin (1975) reported 
that responders to AMI excreted signifi-
cantly higher MHPG than did the non 
responders. These findings led to the 
conclusions that there may be two groups-
one with low MHPG excretion and the 
other with high level. The group with 
low level are associated with an alteration 
in NE system show favourable response 
to IMI or DMI and poor response to 
AMI, the group with high MHPG 
showed favourable response to AMI, 
failure to respond to IMI and associated 
with alteration in ;>HT system (Maas et 
al., 1972). It is to be noted here that 
AMI is not an effective blocker ofNk 
uptake but its active metabolite Nortrip-
tyline (NT) is (Maas ct al., 1972). If 
the therapeutic level of NT is maintained, 
the AMI would also give better result in 
depressive with low MHPG excretion. It 
is assumed that the group with 5HT 
deficiency where NT is less useful is NE 
deficient. It is of interest to note that 
Goodwin et al. (1977) showed inverse 
relationship between CSF 5HIAA and 
uinary MHPG. They reported that 
MHPG excretion in the low 5HIAA 
group was significantly higher than in 
the high 5HIAA group. However this 
has not been confirmed by other investi-
gators. Moreover m most of the studies 
either IMI or AMI has been tried and 
there is no known study to hnd out the 
response to combined therapy of IMI 
and AMI. The facilities to measure the 
amine levels and to moniter the blood 
levels of antidepressants are not available 
in most of the places at least in develo-
ping country like India. Hence it is in 
practice to administer combined IMI and 
AMI theraphy, IMI during day time and 
AMI during bed time as it has also 
sedative effect and there is no need to add 
another drug to induce sleep. 
This study was undertaken to find 
out whether both 5HT system and NE 
system were involved in depressives and 
if so in the same manner or not and to 
find out the clinical response to combined 
IMI and AMI therapy. 
Methods and Materials 
The study consisted of 39 depressives, 
22 males and 17 females between the age 
group of 22 and 50 years, admitted to 
Institute of Mental Health, Madras. 
The patients were diagnosed by two 
Psychiatrists in a separate setting based 
on LCD. 9 criteria. Complete physical 
examination was done by a Physician and 
ruled out neurological and other somatic 
illnesses. Routine laboratory investiga-
tions were carried for all patients and 
few had GAT scan. All the patients were 
administered Hamilton Depression Rating 
Scale (HDRS-24 item version) to assess 
the severity of the illness. 
Laboratory Investigations 
All the patients were drug free for 
atleast three weeks prior to the investiga-
tion. They were all asked not to take any 
drug and to avoid completely banana, 
coffee, tea, cigarette etc prior to the inve-
stigation as they might alter the level of 
the amine metabolite 5HIAA and 
MHPG. Lumbar puncture was done 226  V. PALANIAPPUN et el. 
with extreme precaution as per the stan-
dard procedure and GSF collected. 
Ascorbic acid was added to GSF as pre-
servative and immeidately kept in deep 
freez. Two 24 hrs. urine collection was 
done for all the patients for estimation of 
MHPG and N/6 HCL was added as 
preservative. 
Folio jj-up and drug therapy 
All the patients were started on combined 
Iraipramine (IMI) and Amitriptyline 
(AMI) drugs. Initially IMI was started 
with 50mg during day time in divided doses 
and AMI 25mg during bed time. Slowly 
the dose was increased to maximum 
dosage of IMI during day time in divided 
dose and AMI at bed time. The dose was 
adjusted according to the patients need. 
Few patients had in addition benzodia-
zepenes at bed time and none of the 
patients in this series had received electro-
convulsive therapy. There were no side 
effects reported except minor side effects 
like dryness of mouth, constipation etc. 
Each patient was followed up regularly 
and interviewed by the same psychiatrists 
every week. They were taken up for 
biochemical study once there was clinical 
improvement and after assessing by admi-
nistering Hamilton Depression Rating 
Scale. The interval period between 
initial and second study (after clinical 
improvement) was not same for all the 
patients as the criteria was the clinical 
improvement and improvement on Hami-
lton score and not the interval period. 
Collection of urine and GSF was done as 
for die initial study. Drug free period 
could not be maintained here due to 
ethical reasons. 
formal controls 
The normal control consisted of 17 
persons in whom no physical illnesses 
were detected and these were the persons 
admitted for minor surgical procedures 
under spinal aneasthesia. All these 
persons were seen by physician and two 
psychiatrists and ruled out the possibility 
of any physical and psychiatric illness. 
None of their first degree relatives suffered 
from psychiatric illness. Hamilton De-
pression Rating Scale was administered 
as a second screening tool. CSF and 24 
hours urine collection were done as des-
cribed above. 
Biochemical analysis 
MHPG in urine was estimated 
essentially by the method ofRuthven and 
Sandler (1965) and 5HIAA in GSF essen-
tially by the method of Korf et al. (1971
s. 
All estimations were carried out within 
next 48 hours after collection of specimen. 
Each patient was given code number and 
this was broken only at the end of the 
study for data analysis. Clinicians and 
laboratory personel were blind to each 
others result. 
Results 
It has been reported that urinary 
MHPG and GSF 5HIAA were altered 
in depressives. To find out meaningful 
association between these amine metabo-
lites and severity of depression, Hamilton 
score and the level of these metabolite* 
were correlated. It was observed thai 
there were negative correlation between 
total Hamilton score and urinary MHPG 
(Go-effecient-0.1160, NS) and GSF 
5HIAA(Ck>-cflicient-0.1250, NS) but not 
statistically significant. This did not 
suggest any strong association between 
these amine metabolites and severity of 
depression. 
The urinary MHPG and CSV 
5HIAA of all the depressives were com-
pared with that of normal controls. It 
showed significantly lower level in depre-
ssives (p<.001, Table-In It was of 
interest to note that MHPG and 5HIAA, 
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TABLE I— Comparison of Amine Metaboli-
te i in Depression with Normals 
(•roup  Mean  S.D. 
IrinaryMHPG. Ug/24hrs. 
Depression (N-39) 1.46 
Normals (N-17) 2.96 
t-31.88,p<.001 
OSF5HIAAng/ml. 
Depression (N««39)  18.50 
Normals (N-17) 41.99 
t-26.88,p<.001 
0.24 
0.11 
5.07 
1.17 
in the same direction. But this did not 
give any idea whether they were altered 
in the same manner and in the same 
proportion in all the depressives studied. 
To find out this, all depressives were 
studied individually. All the depressives 
were split into groups with low or high 
MHPG excretors and with low or high 
5HIAA in GSF. As it was reported by 
Maas et al. (1972) that patients with 
urinary excretion less than lOOOUg^ 
hours responded well to IMI therapy, 
this level was taken as criteria to divide 
high and low. Likewise for CSK 51IIAA 
the level of 15ng/ml. was taken as 
criteria to divide as Low and High 
5HIAA group. This was based on the 
study of Asberg et al. (1972) who found 
that the therapautic effect of Nortripty-
line (NT) which is a relatively selective 
inhibitor of NfL group was less pro-
nounced in depressive patient with GSF 
5HIAA level of less than I5ng/ml. 
When it was analysed they lbrmcd four 
groups—1. Low MHPG-Low 5HIAA 
(N-2); 2. Low MHPG-High 5HIAA 
(N-10j; 3. High MHPG-High 511IAA 
(N-14); and 4. High MHPG-Low 5HIAA 
(N-13). The total Hamilton score before 
and after treatment were compared and 
the mean differences were taken which 
obviously shows the degree of clinical 
improvement. The clinical improvement 
as reflected o:i Hamilton score was due 
to the impact of drug treatment mainly. 
The mem score of each group were 
compared to assess the dillcrctial clinical 
improvement (Table-II). It was obser-
ved that there were no difference in the 
Groups 
TABLE II—Comparison between groups on mean increase in Hamillon score 
Mean  S.D.  N 
Low MHPG-Low 5HIAA 
Low MHPG-High 5HIAA 
High MHPG-Low 5HIAA 
Low MHPG-High 5HIAA 
High MHPG-High 5HIAA 
Low MHPG-High 5HIAA 
High MHPG-Low 5HIAA 
High MHPG-High 5HIAA 
Low MHPG-Low 5HIAA 
High MHPG-Low 5HIAA 
Low MHPG-Low 5HIAA 
High MHPG-Low 5HIAA 
31.00 
24.10 
28.23 
24.10 
24.14 
24.10 
28.23 
24.10 
31.00 
28.23 
31.00 
24.14 
5.00 
3.67 
6.01 
3.67 
9.12 
3.67 
6.01 
9.12 
5.00 
6.01 
5.00 
9.12 
•7 
10 
13 
10 
14 
10 
13 
14 
2 
13 
2 
14 
1.86 
.94 
o.»l 
1.33 
0.78 
1.15 
.10 
.10 
NS 
NS 
NS 
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mean increase Hamilton score between 
the groups except the difference between 
Low MHPG-High 5HIAA group and 
Low MHPG-Low 5HIAA group and 
between Low MHPG-High 5HIAA 
group and High MHPG-Low 5HIAA 
groups (p<.01). It was also observed 
that when the four groups were com-
pared, the groups with low nHIAA had 
more mean increase on Hamilton score. 
Discussion 
The differences in drug action can 
assume clinical importance when we 
define biological sub groups of depression 
which respond consistently to specific 
drug. The existence of biological sub 
group has been advocated earlier (van 
Praag, 1977; Asberg etal., 1976; Schi-
Idkraut et al., 1978). The findings of 
lower level of urinary MHPG and CSF 
5HIAA in this study were consistent 
with many earlier reports. The fact that 
urinary MHPG and GSF 5HIAA were 
altered in the same manner in all depre-
ssives propose the hypothesis that in all 
depressives both NE and 5HT systems 
were involved in the same manner. In 
5HT deficient depressives the therapautic 
effect of an antidepressant with most NE 
potentiating effect-NT was less marked 
than that in patients without demon-
strable defect in central 5HT (van Praag, 
1977c). It is assumed to expect these 
NT susceptible patients are NE deficient. 
Maas et al. (1972) proposed that depres-
sives associated with high urinary 
excretion of MHPG who respond better 
to AMI and had abnormally associated 
5HT system. It is noteworthy to point 
that Sacchctti et al. (1976) reported that 
in a small sample that low MHPG depre-
ssives responded to AMI. In the present 
study of 39 subjects, only 10 had low 
MHPG-High 5HIAA and 13 had high 
MHPG-low 5HIAA. It was assumed 
that the former group would respond to 
IMI or NT and the latter to AMI or 
Cloimipramine. In this series, the rest 
16 subjects did not have the expected 
MHPG and 5HIAA alteration. Diagno-
sticaliy all 39 form a homogenous group. 
If one would select a drug for the above 
mentioned 16 depressives, it might be 
difficult to choose whether AMI or IMI. 
AMI is probably not an effect blocker 
of NE uptake but its active metabolite 
NT is (Maas et al., 1972). Hence it 
might be true that AMI would be an 
ideal and would be effective in both 5HT 
and NE deficient groups, provided the 
plasma level of NT is within the thera-
pautic range. Here NT is an active 
metabolite of AMI and there is report to 
assess the dosage of AMI to have the 
therapautic level ol its metabolite. The 
depressives of this two groups (N-16) 
might or might not respond to one group 
of drug alone (either IMI or AMI). The 
rationale that all our patients were put 
on combined therapy of IMI and AMI 
is understood here and the drug started 
without knowing the levels of MHPG or 
5HIAA and plasma levels of drugs were 
not measured. 
The results showed equal improve-
ment as reflected on Hamilton score. 
This means that all depressives responded 
equally to combined therapy of IMI and 
AMI. For NT, IMI and AMI, there were 
studies that have shown correlation bet-
ween plasma levels and therapeutic effect 
(Burrows et al., 1972; Muscettolaetal., 
1978). The therapeutic range for plasma 
concentration in the case of IMI is con-
fined by lower therapeutic and an upper 
toxic limit (Gram et al., 1976). These 
studies indicate a lower critical limit of 
plasma level of 200 to 250ng/ml for total 
concentration of IMI and AMI. Very 
high levels were not associated with good 
or poor response but to toxic effect. In 
the present study, the optimum dosage 
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Even though dose/plasma concentration 
relationship might not be same for all 
patients, it was reasonably expected to 
have the therapeutic level. The altered 
NE system might also be acted by NT, 
the active metabolite of AMI. In the 
NT lower and upper therapeutic plasma 
concentration range has been established 
(Montgomery et al., 1978; Ziegler et al, 
1977). AMI has been studied by several 
authors. Where plasma/effect relation-
ship has been found, there has been a 
positive correlation (Braithwaite et al., 
1972; Ziegler et al., 1977). The study 
by Kupfer et al. (1977) clearly indicated 
that the high level of AMI and/or NT 
were not associated with unfavourable 
therapeutic effect. Pharmacokinetic fac-
tors may be of some importance and for 
a drug like AMI one may speculate if 
the combination with other compounds 
may create new avenue. There is no 
known study to the authors knowledge 
which report about the interaction bet-
ween the different drugs in Tricyclic 
antidepressant (TGA) and the dose/ 
plasma concentration relation when they 
are given in combination. The clinical 
use of plasma monitoring of TCA raise 
the question of how the dose can be 
adjusted early in the course of treatment 
in order to bring the plasma concentra-
tion on an appropriate therapeutic level. 
It was observed from the table II 
that the group which had more mean 
increase on Hamilton score in compari-
son, the level of 5HIAA were low. 
Probably the level of 5HIAA or the 
depressives with 5HT alteration towards 
lower was more significant than urinary 
MHPG. In comparison of two groups 
with high 5HIAA level in both groups, 
the mean increase on Hamilton were 
exactly similar (24.10 and 24.14). Here 
the level of MHPG varied. It might be 
noted that the depressives with Low 
MHPG-Low 5HIAA responded more 
than the other groups. The group which 
showed good improvement next to that 
was high MHPG-Low 5HIAA. The 
group with Low MHPG-Low 5HIAA 
responded better than the other may be 
explained that IMI acted upon NE sys-
tem and AMI acted upon 5HT system 
and increased their levels But this 
interpretation should be given cautiously 
since the sample in this group is very 
small (N-2). Moreover plasma concen-
tration of these drugs were not measured. 
The group with high MHPG-low 5HIAA 
level might be in support of the hypo-
thesis of involvement of 5HT system 
rather than NE system and might have 
been acted upon by AMI. The inter-
pretations arc highly hypothetical and 
further studies arc needed with larger 
samples with estimations of plasma con-
centration of drugs. 
The reason for not finding out the 
alterations in the assumed manner were 
not clear. However, there was one flaw 
in this method of defining low or high 
MHPG or 5HIAA. There is no uni-
versally accepted criteria by which it may 
be categorised as low or high. It was our 
own criteria arrived at, based on tome 
previous studies. What we called as 
high MHPG or 5HIAA might be still 
lower than that of the normals. It was 
only relative term. It was also noted 
that no single patient had normal or 
higher than normal urinary MHPG or 
CSF 5HIAA. The mode of admini-
stering these combination was also to be 
noted. Both of them were not combined 
together during day time or night but 
IMI was administered during day time 
in divided doses and AMI at bed time 
as single dose. The obvious reason for 
administering AMI at bed time was that 
it has sedative effect also. 
The present investigation led to the 
following conclusions. The depressives 
excreted less MHPG and had less CSF 230  V. PALANIAPPUN et al. 
5HIAA than that of normals, their levels 
were negatively correlated with the 
severity of depression though not upto 
statistically significant level, both were 
not, altered in the same direction in all 
depressives and all the depressives showed 
equal therapeutic response to combined 
therapy of IMI and AMI as shown on 
Hamilton score. 
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